Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Japanese Journal of Radiology
Published in: Japanese Journal of Radiology 6/2019

01-06-2019 | Radiotherapy | Original Article

Radiation with concomitant superselective intra-arterial cisplatin infusion for maxillary sinus squamous cell carcinoma

Authors: Takeshi Ebara, Ken Ando, Jun Eishima, Masami Suzuki, Takeshi Kawakami, Hiroyuki Horikoshi, Yoshio Tamaki

Published in: Japanese Journal of Radiology | Issue 6/2019

Login to get access

Abstract

Purpose

To assess the efficacy and prognostic factors after superselective intra-arterial chemoradiation (RADPLAT) for maxillary sinus squamous cell carcinoma (MS-SCC).

Materials and methods

Prognostic significance of age, gender, T and N factors, gross tumor volume of the primary-site (GTV), total cisplatin dosage, and total cisplatin dosage per GTV (CDDP/GTV) for primary-site recurrence-free survival rate (PRFS) were analyzed. RADPLAT was administered to 27 patients. The median follow-up period was 42.1 months.

Results

The 3-year rates of overall survival and PRFS were 59.2% and 53.9%, respectively. In univariate analysis, age, male, and total cisplatin dosage were significant factors for PRFS. In multivariate analysis, lymph node metastasis was significant factors for PRFS, and gender and total cisplatin dosage weakly influenced PRFS. In acute phase, no patient showed ≥ grade 3 hematologic toxicity, and grade 3 mucositis developed in 5 patients. Late toxicities were recognized in 3 patients (grade 2 phlegmon of the face, grade 3 maxillofacial osteonecrosis, and retinopathy). Twelve patients (44%) experienced recurrences. Of them, 8 patients showed recurrence at the primarysite.

Conclusion

RADPLAT was effective for MS-SCC, with acceptable toxicity. Total cisplatin dosage is suggested to be important for primary tumor control.
Literature
1.
Committee JSfhaNCCR. Report of Head and Neck Cancer Registry of Japan Clinical Statistics of Registered Patients, 2015.
2.
Ogawa K, Toita T, Kakinohana Y, et al. Postoperative radiotherapy for squamous cell carcinoma of the maxillary sinus: analysis of local control and late complications. Oncol Rep. 2001;8:315–9.PubMed
3.
Bristol IJ, Ahamad A, Garden AS, et al. Postoperative radiotherapy for maxillary sinus cancer: long-term outcomes and toxicities of treatment. Int J Radiat Oncol Biol Phys. 2007;68:719–30.CrossRefPubMed
4.
Hayashi T, Nonaka S, Bandoh N, Kobayashi Y, Imada M, Harabuchi Y. Treatment outcome of maxillary sinus squamous cell carcinoma. Cancer. 2001;92:1495–503.CrossRefPubMed
5.
Yoshimura R, Shibuya H, Ogura I, et al. Trimodal combination therapy for maxillary sinus carcinoma. Int J Radiat Oncol Biol Phys. 2002;53:656–63.CrossRefPubMed
6.
Shiga K, Yokoyama J, Hashimoto S, et al. Combined therapy after superselective arterial cisplatin infusion to treat maxillary squamous cell carcinoma. Otolaryngol Head Neck Surg. 2007;136:1003–9.CrossRefPubMed
7.
Homma A, Oridate N, Suzuki F, et al. Superselective high-dose cisplatin infusion with concomitant radiotherapy in patients with advanced cancer of the nasal cavity and paranasal sinuses: a single institution experience. Cancer. 2009;115:4705–14.CrossRefPubMed
8.
Homma A, Sakashita T, Yoshida D, et al. Superselective intra-arterial cisplatin infusion and concomitant radiotherapy for maxillary sinus cancer. Br J Cancer. 2013;109:2980–6.CrossRefPubMedPubMedCentral
9.
Robbins KT, Kumar P, Harris J, et al. Supradose intra-arterial cisplatin and concurrent radiation therapy for the treatment of stage IV head and neck squamous cell carcinoma is feasible and efficacious in a multi-institutional setting: results of Radiation Therapy Oncology Group Trial 9615. J Clin Oncol. 2005;23:1447–544.CrossRefPubMed
10.
Ethics guideline for medical research concerning humans. Ministry of education, culture, sports, science and technology, Japan. December 22, 2014.
11.
Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS. March 31, 2003.
12.
Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transpl. 2013;48:452–8.CrossRef
13.
Homma A, Onimaru R, Matsuura K, et al. Dose-finding and efficacy confirmation trial of the superselective intra-arterial infusion of cisplatin and concomitant radiotherapy for locally advanced maxillary sinus cancer (Japan Clinical Oncology Group 1212): Dose-finding phase. Head Neck. 2018;40:475–84.CrossRefPubMed
14.
Robbins KT, Hoffman RM. "Decadose" effects of cisplatin on squamous cell carcinoma of the upper aerodigestive tract I. Histoculture experiments. Laryngoscope. 1996;106:32–6.CrossRefPubMed
15.
Robbins KT, Storniolo AM, Hryniuk WM, Howell SB. "Decadose" effects of cisplatin on squamous cell carcinoma of the upper aerodigestive tract II. Clinical studies. Laryngoscope. 1996;106:37–42.CrossRefPubMed
16.
Rasch CR, Hauptmann M, Schornagel J, et al. Intra-arterial versus intravenous chemoradiation for advanced head and neck cancer: results of a randomized phase 3 trial. Cancer. 2010;116:2159–65.CrossRefPubMed
17.
Al-Mamgani A, Monserez D, Rooij P, Verduijn GM, Hardillo JA, Levendag PC. Highly-conformal intensity-modulated radiotherapy reduced toxicity without jeopardizing outcome in patients with paranasal sinus cancer treated by surgery and radiotherapy or (chemo)radiation. Oral Oncol. 2012;48:905–11.CrossRefPubMed
18.
Suh YG, Lee CG, Kim H, et al. Treatment outcomes of intensity-modulated radiotherapy versus 3D conformal radiotherapy for patients with maxillary sinus cancer in the postoperative setting. Head Neck. 2016;38(Suppl 1):E207–E213213.CrossRefPubMed
19.
Paulino A, Fisher S, Marks J. Is prophylactic neck irradiation indicated in patients with squamous cell carcinoma of the maxillary sinus? Int J Radiat Oncol Biol Phys. 1997;39:283–9.CrossRefPubMed
20.
Le QT, Fu KK, Kaplan MJ, Terris DJ, Fee WE, Goffinet DR. Lymph node metastasis in maxillary sinus carcinoma. Int J Radiat Oncol Biol Phys. 2000;46:541–9.CrossRefPubMed
Metadata
Title
Radiation with concomitant superselective intra-arterial cisplatin infusion for maxillary sinus squamous cell carcinoma
Authors
Takeshi Ebara
Ken Ando
Jun Eishima
Masami Suzuki
Takeshi Kawakami
Hiroyuki Horikoshi
Yoshio Tamaki
Publication date
01-06-2019
Publisher
Springer Japan
Keyword
Radiotherapy
Published in
Japanese Journal of Radiology / Issue 6/2019
Print ISSN: 1867-1071
Electronic ISSN: 1867-108X
DOI
https://doi.org/10.1007/s11604-019-00827-1

Other articles of this Issue 6/2019

Japanese Journal of Radiology 6/2019 Go to the issue

Original Article

Distinction between benign and malignant breast masses at breast ultrasound using deep learning method with convolutional neural network

Original Article

Cryoablation of renal cell carcinoma for patients with stage 4 or 5 non-dialysis chronic kidney disease

Original Article

Changes in tissue gadolinium biodistribution measured in an animal model exposed to four chelating agents

Original Article

Change in hepatic hemodynamics assessed by hepatic arterial blood pressure and computed tomography during hepatic angiography with the double balloon technique

Original Article

Ethanol fixation method for heart and lung imaging in micro-CT

Original Article

Detectability of the choroid plexus of the third ventricle with magnetic resonance ventriculography